CPS Announces First Quarter 2024 Earnings Revenues of $91.7 million compared to $83.1 million in the prior year periodPretax income of $6.6 millionNet income of $4.6 million, or $0.19 per diluted shareNew contract purchases of $346.3 million LAS VEGAS, NV, May 10, 2024 (GLOBE NEWSWIRE) -- Consumer Portfolio Services, Inc. (Nasdaq: CPSS) (“CPS” or the “Company”) today announced earnings of $4.6 million, or $0.19 per diluted share, for its first quarter ended March 31, 2024. This compares to a net income of $13.8 million, or $0.54 per diluted share, in the first quarter of 2023. R...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 20,250 shares of its common stock to eleven newly-hired employees, with a grant date of May 6, 2024 (the "Grant Date"). The restricted stock units were granted pursua...
TELA Bio Reports First Quarter 2024 Financial Results MALVERN, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions today reported financial results for the first quarter ended March 31, 2024. Recent Highlights Reported revenue of $16.6 million in the first quarter, representing growth of 39% over the prior year period of 2023;Delivered the 13th consecutive quarter of at least 35% year-over-year growth;Increased demand for OviTex® and OviTex PRS Reinforced Tis...
Oncternal Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results Fourth dosing cohort at 300 mg per day is fully enrolled for the Phase 1/2 study with ONCT-534, our dual-action androgen receptor inhibitor (DAARI), for patients with advanced prostate cancer who are resistant to approved androgen receptor pathway inhibitors; initial data readout expected in the latter part of the second quarterPhase 1/2 study for ONCT-808, our ROR1-targeting autologous CAR T cell therapy, for patients with relapsed or refractory aggressive B-cell lymphoma, including patients ...
Moody's Ratings (Moody's) assigned a Ba1 rating to new backed senior secured notes to be issued at Charter Communications, Inc.'s (Charter or the Company) wholly owned subsidiaries Charter Communications Operating, LLC (CCO or the company) and co-borrowed by Charter Communications Operating Capital ...
Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights - Completed SNS-101 monotherapy and combination dose escalation through 15mg/kg with no dose limiting toxicities - - Company to present topline clinical data from the SNS-101 Phase 1 dose escalation study at the 2024 ASCO Annual Meeting - - Enrollment in the dose expansion portion of the clinical study advancing - - Strong balance sheet with cash runway into fourth quarter of 2025 - BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage imm...
Chris McDermott Joins Meridian Bank as SVP, Commercial Lending MALVERN, Pa., May 08, 2024 (GLOBE NEWSWIRE) -- Meridian Bank announced the appointment of Christopher E. McDermott to the position of Senior Vice President, Commercial Lending. He’ll join other members of the Meridian Commercial Lending Team in serving business customers in Bucks and Montgomery Counties. Chris began his long banking career right out of high school. He started as a clerk at Girard Bank and advanced through that organization while he simultaneously earned his degree in finance from LaSalle College. Moving from ...
Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wednesday, May 15, 2024 CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its first quarter 2024 financial results and provide an update on its business and pipeline on Wednesday, May 15, after the market close. The Company does not inten...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.